176 related articles for article (PubMed ID: 38192415)
1. Therapeutic efficacy of rare earth carbonate with chemoradiotherapy in late-stage non-small cell lung cancer: a cohort prospective study.
Cao Q; Ye X; Wu X; Zhang Q; Gong J; Chen Y; You Y; Shen J; Qiang Y; Cao G
Front Endocrinol (Lausanne); 2023; 14():1301032. PubMed ID: 38192415
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
Dong XJ; Wang MZ; Zhong W; Zhang L; Zhang XT; Zhao J; Xia Y; Li LY
Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):216-21. PubMed ID: 22780978
[TBL] [Abstract][Full Text] [Related]
3. HELPER study: A phase II trial of continuous infusion of endostar combined with concurrent etoposide plus cisplatin and radiotherapy for treatment of unresectable stage III non-small-cell lung cancer.
Zhai Y; Ma H; Hui Z; Zhao L; Li D; Liang J; Wang X; Xu L; Chen B; Tang Y; Wu R; Xu Y; Pang Q; Chen M; Wang L
Radiother Oncol; 2019 Feb; 131():27-34. PubMed ID: 30773184
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: a subgroup analysis of a randomized phase III trial.
Bi N; Liu L; Liang J; Wu S; Chen M; Lv C; Zhao L; Shi A; Jiang W; Xu Y; Zhou Z; Wang J; Wang W; Chen D; Hui Z; Lv J; Zhang H; Feng Q; Xiao Z; Wang X; Zhang T; Yin W; Li J; He J; Wang L
BMC Cancer; 2020 Apr; 20(1):278. PubMed ID: 32252680
[TBL] [Abstract][Full Text] [Related]
5. Phase III Study of Surgery Versus Definitive Concurrent Chemoradiotherapy Boost in Patients With Resectable Stage IIIA(N2) and Selected IIIB Non-Small-Cell Lung Cancer After Induction Chemotherapy and Concurrent Chemoradiotherapy (ESPATUE).
Eberhardt WE; Pöttgen C; Gauler TC; Friedel G; Veit S; Heinrich V; Welter S; Budach W; Spengler W; Kimmich M; Fischer B; Schmidberger H; De Ruysscher D; Belka C; Cordes S; Hepp R; Lütke-Brintrup D; Lehmann N; Schuler M; Jöckel KH; Stamatis G; Stuschke M
J Clin Oncol; 2015 Dec; 33(35):4194-201. PubMed ID: 26527789
[TBL] [Abstract][Full Text] [Related]
6. Concurrent chemoradiotherapy with vinorelbine plus split-dose cisplatin may be an option in inoperable stage III non-small cell lung cancer: a single-center experience.
Mertsoylu H; Köse F; Sümbül AT; Sedef AM; Doğan Ö; Besen AA; Parlak C; Fındıkçıoğlu A; Muallaoğlu S; Sezer A; Sakallı H; Özyılkan Ö
Med Sci Monit; 2015 Mar; 21():661-6. PubMed ID: 25731741
[TBL] [Abstract][Full Text] [Related]
7. Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer (RTOG 0617): a randomised, two-by-two factorial phase 3 study.
Bradley JD; Paulus R; Komaki R; Masters G; Blumenschein G; Schild S; Bogart J; Hu C; Forster K; Magliocco A; Kavadi V; Garces YI; Narayan S; Iyengar P; Robinson C; Wynn RB; Koprowski C; Meng J; Beitler J; Gaur R; Curran W; Choy H
Lancet Oncol; 2015 Feb; 16(2):187-99. PubMed ID: 25601342
[TBL] [Abstract][Full Text] [Related]
8. Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials.
Honglian M; Zhouguang H; Fang P; Lujun Z; Dongming L; Yujin X; Yong B; Liming X; Yirui Z; Xiao H; Jin W; Yue K; Lvhua W; Ming C
Thorac Cancer; 2020 Apr; 11(4):898-906. PubMed ID: 32068962
[TBL] [Abstract][Full Text] [Related]
9. Combination of Iodine-125 brachytherapy and chemotherapy for locally recurrent stage III non-small cell lung cancer after concurrent chemoradiotherapy.
Yu X; Li J; Zhong X; He J
BMC Cancer; 2015 Oct; 15():656. PubMed ID: 26445227
[TBL] [Abstract][Full Text] [Related]
10. Prognostic Significance of Standardized Uptake Value of Lymph Nodes on Survival for Stage III Non-small Cell Lung Cancer Treated With Definitive Concurrent Chemoradiotherapy.
Lee VH; Chan WW; Lee EY; Choy TS; Ho PP; Leung DK; Lam KO; Kwong DL; Leung TW; Khong PL
Am J Clin Oncol; 2016 Aug; 39(4):355-62. PubMed ID: 24710123
[TBL] [Abstract][Full Text] [Related]
11. Concurrent EGFR-TKI and Thoracic Radiotherapy as First-Line Treatment for Stage IV Non-Small Cell Lung Cancer Harboring EGFR Active Mutations.
Zheng L; Wang Y; Xu Z; Yang Q; Zhu G; Liao XY; Chen X; Zhu B; Duan Y; Sun J
Oncologist; 2019 Aug; 24(8):1031-e612. PubMed ID: 31040256
[TBL] [Abstract][Full Text] [Related]
12. Fasting plasma glucose is an independent predictor of survival in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Bergamino M; Rullan AJ; Saigí M; Peiró I; Montanya E; Palmero R; Ruffinelli JC; Navarro A; Arnaiz MD; Brao I; Aso S; Padrones S; Cardenal F; Nadal E
BMC Cancer; 2019 Feb; 19(1):165. PubMed ID: 30791870
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of recombinant human endostatin combined with radiotherapy or chemoradiotherapy in patients with locally advanced non-small cell lung cancer: a pooled analysis.
Zhang SL; Han CB; Sun L; Huang LT; Ma JT
Radiat Oncol; 2020 Aug; 15(1):205. PubMed ID: 32831120
[TBL] [Abstract][Full Text] [Related]
14. Introducing FDG PET/CT-guided chemoradiotherapy for stage III NSCLC in low- and middle-income countries: preliminary results from the IAEA PERTAIN trial.
Konert T; Vogel WV; Paez D; Polo A; Fidarova E; Carvalho H; Duarte PS; Zuliani AC; Santos AO; Altuhhova D; Karusoo L; Kapoor R; Sood A; Khader J; Al-Ibraheem A; Numair Y; Abubaker S; Soydal C; Kütük T; Le TA; Canh NX; Bieu BQ; Ha LN; Belderbos JSA; MacManus MP; Thorwarth D; Hanna GG
Eur J Nucl Med Mol Imaging; 2019 Oct; 46(11):2235-2243. PubMed ID: 31367906
[TBL] [Abstract][Full Text] [Related]
15. Phase 1 Trial of Pembrolizumab Administered Concurrently With Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer: A Nonrandomized Controlled Trial.
Jabbour SK; Berman AT; Decker RH; Lin Y; Feigenberg SJ; Gettinger SN; Aggarwal C; Langer CJ; Simone CB; Bradley JD; Aisner J; Malhotra J
JAMA Oncol; 2020 Jun; 6(6):848-855. PubMed ID: 32077891
[TBL] [Abstract][Full Text] [Related]
16. Phase II study of induction chemotherapy with gemcitabine and vinorelbine followed by concurrent chemoradiotherapy with oral etoposide and cisplatin in patients with inoperable stage III non-small-cell lung cancer.
Lee DH; Han JY; Cho KH; Pyo HR; Kim HY; Yoon SJ; Lee JS
Int J Radiat Oncol Biol Phys; 2005 Nov; 63(4):1037-44. PubMed ID: 16024178
[TBL] [Abstract][Full Text] [Related]
17. Planning target volume as a predictor of disease progression in inoperable stage III non-small cell lung cancer patients treated with chemoradiotherapy and concurrent and/or sequential immune checkpoint inhibition.
Taugner J; Käsmann L; Karin M; Eze C; Flörsch B; Guggenberger J; Li M; Tufman A; Reinmuth N; Duell T; Belka C; Manapov F
Invest New Drugs; 2022 Feb; 40(1):163-171. PubMed ID: 34351518
[TBL] [Abstract][Full Text] [Related]
18. Comparison of Concurrent Use of Thoracic Radiation With Either Carboplatin-Paclitaxel or Cisplatin-Etoposide for Patients With Stage III Non-Small-Cell Lung Cancer: A Systematic Review.
Steuer CE; Behera M; Ernani V; Higgins KA; Saba NF; Shin DM; Pakkala S; Pillai RN; Owonikoko TK; Curran WJ; Belani CP; Khuri FR; Ramalingam SS
JAMA Oncol; 2017 Aug; 3(8):1120-1129. PubMed ID: 27978552
[TBL] [Abstract][Full Text] [Related]
19. Predictive relevance of PD-L1 expression combined with CD8+ TIL density in stage III non-small cell lung cancer patients receiving concurrent chemoradiotherapy.
Tokito T; Azuma K; Kawahara A; Ishii H; Yamada K; Matsuo N; Kinoshita T; Mizukami N; Ono H; Kage M; Hoshino T
Eur J Cancer; 2016 Mar; 55():7-14. PubMed ID: 26771872
[TBL] [Abstract][Full Text] [Related]
20. Dynamic evaluation of neutrophil-to-lymphocyte ratio as prognostic factor in stage III non-small cell lung cancer treated with chemoradiotherapy.
Palomar-Abril V; Soria-Comes T; Campos ST; Ureste MM; Bosch VG; Maiques ICM
Clin Transl Oncol; 2020 Dec; 22(12):2333-2340. PubMed ID: 32449125
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
